In liver fibrosis, RUNX2 has been reported to activate hepatic stellate cells (HSCs) by upregulating Itgav expression and functioning as a transcriptional inhibitor of SLC27A5, resulting in the buildup of cholic acid and subsequent activation of HSCs. Here, RUNX2 is linked to Hepatic fibrosis.